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Abstract
Purpose: Confirmation of treatment delivery accuracy in stereotactic body radiotherapy (SBRT) of lung tumors suggests the
possibility of treatment margin, or aperture reduction. In this investigation, the dose delivery to lung tumors using SBRT tech-
niques was verified, and the feasibility of normal tissue sparing via aperture reduction or altered prescription isodose line was
assessed. Methods: Planned and delivered doses to the gross tumor volume (GTV) and planning target volume (PTV) were
compared for 10 patients using planning CT and conebeam CT image. Potential for reduction in normal tissue dose were as-
sessed using 2 alternate treatment plans – reduced PTVs and alternate prescription techniques. Plans were assessed using con-
formity index, homogeneity index and the ratio of 50% / 100% isodose volumes (R50%). Results: The planned and delivered
mean doses were consistent to within 4%. However, the mean dose delivered to the GTV exceeded the prescription dose (Rx)
by 19% and is consistent with our planning technique of prescribing to the 80% isodose line. When reducing treatment margins
and retaining a constant dose-volume constraint, block margins had to be increased which produced a constant effective field
aperture outside of the GTV. Prescription to a lower isodose line using stereotactic-like planning techniques yielded the only
method by which the volume of the prescription isodose could be affected, although this yielded increases in normal tissue dose
due to the increased monitor units required. Conversely, conventional prescription techniques using wider field apertures were
effective in reducing absolute values of normal tissue dose. Although dose conformity was similar across different prescription
isodose lines, homogeneity index and R50% values were significantly different in the 60%-70% prescription isodose line plans
than the 80%, 90% prescription plans. Conclusion: Traditional margin reduction techniques did not affect a reduction in the
volume of normal tissue irradiated to the prescribed dose. Prescribing to low isodose lines yields reduced volumes of the pre-
scribed dose, but at the expense of normal tissue dose.
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Introduction
Stereotactic body radiation therapy (SBRT) is a widely used
treatment modality for early-stage non-small cell lung can-
cer (NSCLC).1 Stereotactic plans need not only optimum
dose conformity within the target, but also sharp dose fall off
in the normal tissue. There is a mature literature on the effi-
cacy of SBRT, and studies vary in terms of the specifics used
for treatment planning, immobilization and daily setup.2, 3
We began the present investigation to study the degree to
which our planning and treatment techniques result in do-
simetric accuracy.
The results supported the assumption of dose delivery accu-
racy and prompted an investigation into the feasibility of
reducing the planning target volumes (PTVs) for this class of
tumors. This latter investigation revealed certain potentially
counter-intuitive aspects to the prospects of margin reduc-
tion for these very small tumors. Herein, we present our
findings.
Typical SBRT planning strategies presume there to be un-
predictable motion of the gross tumor volume (GTV) within
the PTV, thus justifying the practice of treating volumes of
uninvolved normal tissue. The amplitude of lung tumor mo-
tion is largest along the superior-inferior direction and can
have significant dosimetric impact.4 Several management
strategies have been developed including abdominal com-
pression to reduce the amplitude of target motion 5, 6 respir-
atory gated treatment 7, and patient coaching8. Many clinics
combine more than one of these strategies and hence it is
conceivable that the GTV motion is less than anticipated.2 As
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such, current PTV margin recommendations may require
additional scrutiny. In this study, we identified 2 alternate
treatment planning methods that could potentially reduce
the normal tissue dose and these were reduced PTV margins
and alternate prescription techniques.
Further, we note that there are potential differences between
the dose presented on the treatment plan, the prescribed
dose (Rx) and the presumed delivered dose accounting for
excursions of the GTV within the PTV volume. Yeung et al.9
and Grills et al.10 measured daily setup using cone-beam CT
(CBCT) and suggested the possibility of margin reduction in
lung cancer patients. Galerani et al.11 had performed manual
segmentation of tumor and normal structures directly on the
CBCT image followed by calculation of dose distribution.
However, the Hounsfield unit (HU) inaccuracies that are
present in the CBCT image limit the accuracy with which
the dose can be calculated. Rather than a direct dose calcula-
tion on CBCT data sets, Yang et al.12 used the HUs from
planning CT (pCT) images after registering to the CBCT im-
ages in order to improve the accuracy of dose calculation, an
approach used in this study.
Methods and Materials
Simulation and treatment
Ten patients treated for primary lung cancer with SBRT on a
conventional 21EX linear accelerator (LINAC) (Varian Med-
ical Systems, Palo Alto, CA, USA) were studied, as shown in
Table 1. LINAC was commissioned with 40 pairs of 5 mm
thick multileaf collimators and 6 MeV photon beam for
SBRT. Patients were immobilized during simulation and
treatments using a stereotactic body frame (Elekta, Stock-
holm, Sweden), vacuum shaping bag (Vac-lock, MED-TEC
Inc., Orange City, IA) and abdominal compression.
Patients underwent free-breathing 3D-CT scans using a GE
LightSpeed 16-slice CT scanner (GE Healthcare, Waukesha,
WI) without any formal coaching or intravenous contrast.
4D-CT was not performed on these patients that are a part of
this retrospective study. Before each fraction, a CBCT scan
was acquired using an onboard imaging system (Varian
Medical Systems, Palo Alto, CA, USA).
A total of ten free-breathing pCT scans and thirty eight
CBCT scans were acquired. Three-dimensional conformal
planning was performed using both coplanar and
non-coplanar beams with XiO treatment planning system
(ver 4.50, CMS, St. Louis, USA). A convolution/superposition
algorithm with heterogeneity corrections applied on a grid
size of 2 × 2 × 2 mm3 was used for calculations.
TABLE 1: Tumor characteristics and fractionation schemes of the 10 pa-
tients in our study.
Characteristic Value or Mean Range
No of patients studied: 10
Male 3
Female 7
Age at diagnosis (yrs) 68.4 57 – 78
GTV volume in pCT (cc) 11.3 1.6 – 24.3
PTV volume in pCT (cc) 42.9 12.1 – 81.6
Fractionation:
4 × 12 Gy 6
3 × 18 Gy 2
3 × 20 Gy 1
5 × 11 Gy 1
Tumor distribution:
Right upper lobe 5
Right middle lobe 2
Right lower lobe 0
Left upper lobe 2
Left lower lobe 1
# Non-coplanar fields used:
8 2
10 8
Image registration and transfer of contours
The pCT image with segmented contours and the
pre-treatment CBCT images were transferred to the Fo-
cal-Sim workstation (CMS, St. Louis, USA). Rigid registration
was performed between the pCT and CBCT images using the
target anatomy and verified by the physician. The contours
of regions of interest (ROI) that were transferred following
registration and corrected by the physician include GTV,
PTV and organs at risk (OAR) including spinal cord, esoph-
agus, lungs and heart.
The uncertainty in GTV contouring was assessed by scan-
ning a test object that was oscillated with the QUASARTM
respiratory motion phantom (Modus Medical Devices, On-
tario, CA). pCT and CBCT scans of the phantom were ac-
quired using our clinical techniques and the known test ob-
ject volume was then compared to that of the contoured
volume. The error bars associated with the reported tumor
volume changes were derived from this motion phantom
study.
Comparison between prescription dose, planned dose
and the delivered dose
Contours of the ROIs were drawn on the pre-treatment
CBCT image. These were transferred from the pre-treatment
CBCT image onto the pCT image after registration and cor-
rected by the physician. Due to restricted field of view
(FOV) of the CBCT image compared to the pCT image, the
planned dose was calculated using pCT image within the
FOV of CBCT image. In order to improve the accuracy of the
planned and delivered doses calculations from the dose vol-
ume histogram (DVH), the HU values of only the pCT image
was used in dose calculation. Calculations of dose delivered
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on a fraction were based on the treatment day ROIs trans-
ferred from the corresponding pre-treatment CBCT onto the
pCT.
Reduction in the PTV treatment margin
In this study, we define PTV treatment margin as the margin
that is added to the GTV and in all clinical plans these were
5, 5 and 10 mm along the lateral, anterior/posterior and su-
perior-inferior axes, respectively. We assessed the potential
for reducing the PTV treatment margin by creating five test
plans from the original treatment plan for each patient. Test
plans were denoted as “PTV_X_Y_Z”, referring to the PTV
treatment margins of X, Y, and Z mm along the lateral, ante-
rior/posterior and superior-inferior axes, respectively. The
test plans created in our study were PTV_5_5_10,
PTV_5_5_5, PTV_3_3_7, PTV_3_3_3 and PTV_1_1_1.
In designing the test plans, we applied the dose-volume con-
straint that at least 95% of the PTV received 95% of Rx:
PTV_X_Y_Z V95%Rx > 95% for each of the 5 test plans. In
this study, we define the block margin as the margin that is
added to the PTV in order to obtain the desired dose con-
straint. Majority of SBRT fields need a block margin of 2 mm
and can go up to 5 mm. The field aperture, defined by the
multi-leaf collimator (MLC) position, was opened outside the
PTV_X_Y_Z by a block margin to account for the beam pe-
numbra. In other words, field aperture is the sum total of the
PTV and the block margin. In order to meet the
dose-volume constraint of PTV_X_Y_Z, the corresponding
block margin was incremented along all 3 axes in steps of 1
mm starting with 0 mm. For each of the five test plans pre-
scribed at the 80% isodose line, the lowest block margin
needed for meeting the dose-volume constraint was applied.
The process is outlined in Figure 1 in which the GTV is dis-
played in red, PTV treatment margin in light grey, block
margin is transparent and the field aperture is defined by the
inner edge of the MLCs in green. Figure 1(a) corresponds to
PTV_5_5_10 meeting the dose-volume constraint with 0 mm
block margin. While the PTV_3_3_3 fails to meet the
dose-volume criteria with 0 mm block margin in Figure 1(b),
the same is met with 5 mm block margin as shown in Figure
1(c). The corresponding absolute volume covered by the
100%, 95%, 50% and 20% of prescription isodose lines were
recorded for each of the test plans.
Changes to prescription isodose line
We studied the dosimetric impact of changes in the prescrip-
tion isodose line, with the intent of reducing the irradiated
volume of normal tissue.13 We tested prescriptions to 60%,
70%, 80% and 90% isodose lines, in each of the test plans
upon meeting the dose-volume constraint PTV_X_Y_Z
V95%Rx > 95%. This choice of prescription techniques is
supported by RTOG protocols (RTOG 0915, RTOG 0618)
and represents a range of treatment philosophies. For the
purposes of this study, we construct the following definitions
of the prescription methodologies:
 Full SRS: 60% of global maximum
 Moderated SRS: 70% of global maximum
 Aggressive conventional: 80% of global maximum
 Full conventional: 90% of global maximum
FIG. 1: Plot showing the importance of choosing an optimum block margin in order to meet the dose-volume constraint of the PTV. The GTV is
displayed in solid red, PTV treatment margin in white, block margin is transparent and the field aperture is defined by the inner edge of MLCs
in green. (a) Dose-volume constraint for PTV_5_5_10 (V95%Rx = 99%) is met using 0 mm block margin; (b) While the dose-volume constraint
for PTV_3_3_3 (V95%Rx = 80.1%) fails with 0 mm block margin; (c) It passes (V95%Rx = 95.9%) with 5 mm block margin.
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Plan evaluation
The impact of varying the prescription methodology was
assessed by measuring the absolute tissue volume contained
within the 100%, 95%, 50% and 20% of the prescription
dose as well as global maximum dose. Conformity index (CI)
was defined based on International Commission on Radia-
tion Units and Measurements (ICRU) Report 62 as:=
Homogeneity index (HI) was defined as:= −
Dose fall-off was studied using R50% which was defined as:= 50%
The differences across planning techniques were evaluated
using a 2-tailed paired Student’s T-test and the significance
was established for a p-value < 0.05.
Results
Tumor volume variation with treatment
In this study, non-coplanar, non-opposing, 3D conformal
6MV photon beams were used with 80% isodose line cover-
ing at least 95% of PTV. The treatments are spread across 3-5
days. The fractionation schemes for the 10 patients were as
follows: 4 patients – 12Gy×4 fractions, 2 patients – 18Gy × 3
fractions, 1 patient – 20Gy × 3 fractions and 1 patient – 11Gy
× 5 fractions. The reduction in tumor volume over the course
of therapy was insignificant (p = 0.2 for GTV and p = 0.17 for
PTV) as shown in Figure 2. Before treatment, the mean
volume of the GTV was 11±8 cc (range: 2 – 24 cc) with the
corresponding PTV volume of 43±24 cc (range: 12 – 82 cc).
At the end of treatment, the GTV changed by 0±25% (range:
-33% – 43.5%) and the PTV by 2±15% (range: -20% – 28%),
averaged over all the patients. As such, we were not able to
observe any detectable change in tumor volume over the
course of treatment. The error bars associated with the tu-
mor volumes were derived from the QUASARTM respiratory
motion phantom study.
Comparison between prescription dose, planned dose
and the delivered dose
Delivered dose was calculated for all the ROIs and compared
with the planned dose. The planned and delivered dose to
the OARs including spinal cord, esophagus, lungs and heart
were almost identical without any significant differences
with p-value > 0.15 on a 2-tailed paired Student’s T-test.
While the maximum delivered doses to GTV and PTV did
not change significantly (<0.1%), the minimum delivered
doses to the GTV and PTV deviated by -4±5% and -19±15%,
respectively, when averaged across patients over all frac-
tions. When averaged across patients over all fractions, the
delivered mean dose to the GTV and PTV deviated from the
planned dose respectively by -1 ± 1% and -2 ± 2%, as shown
in Figure 3. A 2-tailed paired Student’s T-test did not reveal
the presence of any statistically significant difference be-
tween planned and delivered doses to GTV and PTV
(p-value > 0.1). The fact that there are small differences be-
tween the mean doses delivered and planned to the GTV, we
infer that the set-up uncertainties have been adequately
compensated via our applied PTV margin.
FIG. 2: Variations in the GTV for the ten lung tumor patients during
treatment are shown. The GTV for fraction #0 is derived from the
pCT whereas the GTV for subsequent treatment fractions was de-
rived from the CBCT. Error bars are derived from a motion phantom
study and are 6% and 7% for the pCT and CBCT, respectively.
FIG. 3: Distribution of percentage differences between the doses
delivered and planned to GTV and PTV are shown along with mean
values in black and grey lines, respectively.
FIG. 4: Prescription radiation dose (Rx) (cGy) as compared with the
maximum, mean and minimum GTV delivered dose (cGy) for the 10
patients is shown. In all cases, the delivered dose exceeds the Rx.
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The data presented thus far suggests that GTV excursions
within the PTV are minimal and result in only minor dosi-
metric differences between the planned and delivered GTV
doses. The intent of the PTV margin is to ensure dosimetric
coverage of the GTV at the prescription isodose level in the
presence of geometric excursions. In all the cases analyzed in
the study, the contours of GTV from the CBCT images were
visually verified to be within the PTV contour in pCT. The
mean planned dose to the GTV is, by design, higher than the
prescription dose, due to the heterogeneous nature of the
dose within the PTV volume, and our practice of prescribing
to the 80% isodose line.
In the absence of geometric excursions, the GTV receives a
higher dose than it would if it was subject to the random or
systematic excursions implied by the application of the PTV
margins of 5, 5 and 10 mm along the lateral, anteri-
or/posterior and superior-inferior axes, respectively. In Fig-
ure 4, we show that the mean dose delivered to the GTV
exceeds the prescription dose by 19% on average. On aver-
age, the minimum delivered dose exceeds the prescription
dose by 8% and the maximum delivered dose by 25%. Data
presented thus far, demonstrate the geometric accuracy of
dose delivery.
Reduction in the PTV treatment margin
In our first investigation into the feasibility of reducing the
volume of irradiated normal tissue, we reduced the PTV
margin. However, during the simulation process, we discov-
ered that it was impossible to meet the prescribed dose vol-
ume constraints without either increasing the field aperture
(i.e., increasing the block margin) or by prescribing to a
lower isodose line. In Figure 5, we show that the required
block margin increased as the PTV margin decreased, ensur-
ing a constant field aperture outside the GTV. For all pa-
tients, the PTV_5_5_10 margin required the smallest block
margin, whereas PTV_1_1_1 required the largest block mar-
gin. Intermediate PTV margins were consistent with this
trend, the sum of the block margin and the 3-axes average of
PTV margin were constant to within 0.7 mm. This had the
net effect of rendering the field aperture (outside the GTV)
to be almost constant, regardless of the PTV margin applied.
This is illustrated using an example shown in Figure 1.
Shown in Figure 1(a), PTV_5_5_10 passes the dose-volume
constraint (PTV_5_5_10 V95%Rx > 95%) with 0 mm block
margin. When PTV treatment margin was shrunk in size, it
fails the dose-volume constraint (PTV_3_3_3 V95%Rx <
95%) with 0 mm block margin, but passes (PTV_3_3_3
V95%Rx > 95%) with 5 mm block margin, as shown in Fig-
ures 1(b) and 1(c), respectively. As stated earlier, the field
aperture width or the sum total of the block margin and the
PTV margin stayed constant to within 0.7 mm for all the 5
test plans. This resulted in very small variation in the volume
of tissue covered by the Rx isodose line. Shown in Figure 6 is
the volume of tissue covered by the Rx isodose line (cc) for
the 10 patients with Rx dose prescribed to the 80% isodose
line (R2 = 0.40). As expected, the Rx isodose volume scales
with GTV, but is not impacted by changes to the PTV treat-
ment margin.
FIG. 5: Block margin (mm) used in creating test plans that met the
dose-volume constraint is inversely related with the 3-axes average
of PTV treatment margin (R2=0.92), such that the total field aperture
is constant to within 0.7 mm (R2=0.097). The data was analyzed for
the 10 treatment plans with Rx dose prescribed to the 80% isodose
line.
FIG. 6: Plot showing the relationship between the volumes covered
by prescription isodose line (cc) and the 3-axes average of the PTV
treatment margin (mm) (R2=0.40), along with volume of gross tumor.
The data were analyzed for the 10 treatment plans with Rx dose
prescribed to the 80% isodose line.
FIG. 7: Plot showing the relation between the volume of clinical
PTV (cc) and the block margin (mm) when averaged across the 5 test
plans for each of the 10 treatment plans.
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FIG. 8: Plot showing the absolute volume (cc) irradiated by the isodose line (as % of maximum dose) for test plans. a) PTV_5_5_10; b)
PTV_1_1_1 in a relatively large tumor (GTV volume = 18.1 cc); c) PTV_5_5_10; and d) PTV_1_1_1 in a relatively small tumor (GTV volume =
1.6cc). The 4 types of prescription techniques used are full SRS (FSRS), moderated SRS (MSRS), aggressive conventional (AC) and full conven-
tional (FC) that correspond to the prescription at 60%, 70%, 80% and 90% of global maximum dose line.
FIG. 9: Volume irradiated by 100%, 95%, 50% and 20% Rx isodose lines (in cc) in a) PTV_5_5_10; b)PTV_1_1_1 in a relatively large tumor
(GTV volume = 18.1cc); c) PTV_5_5_10; and d) PTV_1_1_1 in a relatively small tumor (GTV volume = 1.6cc). Notice the uniform decrease in
volume of %Rx isodose lines with the more conventional planning strategies than with the stereotactic strategies. Full SRS (FSRS) – 60%, Mod-
erated SRS (MSRS) – 70%, Aggressive conventional (AC) – 80%, and Full conventional (FC) – 90% of the global maximum dose.
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FIG. 10: Plot showing the impact of changing PTV treatment margin and prescription isodose line. In (a) 95% of PTV is covered by the pre-
scription isodose line which is set to 95% of the global maximum dose; (b) 95% volume of a relatively smaller PTV is covered by the 60% iso-
dose line, resulting in a larger global maximum dose and usage of higher monitor units.
A similar trend was seen when comparing the average block
margin to the volume of the PTV. The average of the block
margins for the 5 test plans showed negative linear correla-
tion (R2 = 0.73, p-value < 5 × 10-4) with volume of the PTV in
the treatment plan. This is displayed in Figure 7. This is con-
sistent with conventional treatment planning experience, in
which the penumbra from the field aperture encompasses a
relatively small fraction of the target volume and therefore,
smaller block margins may be used for larger PTV while still
adhering to the desired dose volume constraints.
Changes to the prescription isodose line
An alternative to increasing the block margin in order to
meet the PTV_X_Y_Z V95%Rx > 95% planning constraint,
is to prescribe to a lower isodose line. To assess the efficacy
of this strategy, we analyzed the absolute volume of tissue
irradiated by a certain dose level for varying prescription
strategies. Figure 8 shows that the absolute volume of tissue
irradiated by a certain dose level is lowest for the full stereo-
tactic prescription technique (i.e., prescription to the 60%
isodose line), and is highest using full conventional prescrip-
tion techniques (i.e., prescription to the 90% isodose line).
This result is a confirmation of the stereotactic strategies,
such as Gamma Knife treatments, that typically prescribe to
the 50% isodose line in order to achieve a high degree of
conformity.
Figures 8a and 8, correspond to PTV_5_5_10 and
PTV_1_1_1 test plans of a patient with a relatively large
tumor (i.e., GTV volume of 18.1 cc), while Figures 8c and 8d
correspond to a patient with a relatively small tumor (GTV
volume = 1.6 cc). This data confirms the understanding that
prescribing to lower isodose levels (i.e., using a stereotactic
prescription technique) allows for more conformal treatment
and a reduction in the amount of irradiated normal tissue,
especially for small tumors and small target margins. Specif-
ically, the difference in the absolute tissue volume irradiated
between the techniques is greatest in Figure 8d (i.e., small
tumor, small margin), and smallest in Figure 8a (i.e., large
tumor, large margin). However, the difference in the vol-
umes of normal tissue irradiated using the above mentioned
prescription techniques are not statistically significant
(p-value > 0.1) for the representative case and needs to be
studied on a case-by-case basis.
As described above and shown in Figure 9, we expected the
volume of irradiated tissue to decrease with the more aggres-
sive, or stereotactic, types of plans. However, when we plot-
ted the volume of tissue that received 50% of the prescrip-
tion dose, rather than 50% of the global maximum dose, the
data reveal the opposite trend. That is, the more aggressive,
or stereotactic, prescription techniques result in a larger
volume of tissue receiving any given absolute dose, as
demonstrated in Figure 9.
The mechanism responsible for this behavior is the fact that
SRS prescription techniques achieve target coverage by in-
creasing the monitor units and accepting higher “hot spots”,
relative to the prescription dose. Note that this higher global
maximum dose irradiates a small region within the PTV,
thereby increasing the dose inhomogeneity within the PTV.
The large monitor unit settings used in these treatment
techniques contribute additional dose across the patient
volume, including low and high isodose levels. Figures 9a
and 9b correspond to PTV_5_5_10 and PTV_1_1_1 test plans
of a patient with a relatively large tumor (GTV volume =
18.1 cc), while Figures 9c and 9d correspond to a patient
with a relatively small tumor (GTV volume = 1.6 cc).
Plan evaluation
The dosimetric parameters (CI, HI and R50%) evaluated for
the 60% - 90% prescription isodose line plans were tabulated
in Table 2. The values represented were mean ± 1 standard
deviation. CI values were similar between 60%-70% pre-
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scription plans and marginally higher for 80% - 90% pre-
scription plans, but the differences were insignificant
(p-value > 0.1). HI values of 60% prescription plan were sim-
ilar to the 70% prescription plans, but were significantly
higher than both 80% and 90% prescription plans (p-values
0.05). R50% values of 60% prescription plan were significantly
smaller than those of the 70% - 90% prescription plans with
p-values < 0.05.
TABLE 2: Comparison of planning parameters at 60%, 70%, 80%
and 90% prescription isodose lines represented as mean ± 1 standard
deviation across patient plans.
60% 70% 80% 90%
CI 1.20±0.13 1.22±0.1 1.24±0.17 1.28±0.11
HI 0.37±0.05 0.29±0.03 0.22±0.02 0.14±0.02
R50% 3.48±0.23 3.81±0.32 3.93±0.24 4.34±0.32
Discussion
We began this investigation with the goal of assessing
whether our treatment techniques accurately delivered the
planned tumor dose. The results shown in Figures 3 – 4 sug-
gest that our immobilization, planning and daily set-up
techniques result in good dosimetric coverage of the target
volume. Specifically, Figure 4 shows that all GTVs studied
received a mean dose that deviated from the planned dose by
less than 4% and that with one exception, all PTVs received
a mean dose that deviated from the planned dose by less than
4%. With statistically insignificant differences between the
planned and delivered doses to the GTV and PTV, there is
likely very little negative clinical impact to the reduced
minimum dose to the PTV, since we established that the
GTV received the desired dose. An assumption made in the
study is that the positional variation following the CBCT
acquisition and prior to beam-on is negligible. We note that
these results may not translate to different techniques. It is
feasible to study the difference between planned and deliv-
ered biological effective dose (BED) in SBRT of lung tumor
using image guidance and this aspect of radiobiology is not
studied here.14
Of the possible mechanisms of dose discrepancies between
planned and delivered doses, tumor deformation, or growth,
were considered. Figure 2 shows that, for our data, there was
not a statistically significant change in the tumor volume,
suggesting that tumor growth, or shrinkage, is negligible.
The error bars used in this data were derived from a motion
phantom study and are 6% and 7% in the pCT and CBCT
images, respectively.
Figure 5 and Figure 6 illustrate that using the traditional
approach of reducing the PTV margin can have little impact
on the volume of tissue irradiated, especially for smaller tu-
mors. We attribute this to the fact that the small field aper-
tures used in SBRT have a significant portion of their cross
sections contained within the penumbra region. The associ-
ated steep dose fall off degrades the dose coverage dispropor-
tionately for small tumors, requiring an increase in the block
margin, as shown in Figure 7. A similar trend with rapid fall
in the homogeneity index (=maximum PTV dose/Rx dose)
with increasing block margin (referred as “beam margin”)
was seen with the small brain lesions in a stereotactic radio-
surgery study (SRS) by Hong et al.15
We found that the only method by which the volume irra-
diated by a certain dose level can be reduced is to prescribe
to a lower isodose line as shown in Figure 8. As indicated in
Figure 9, this results in an increase in the global maximum
dose and the volume of all absolute dose levels. This implies
that the renormalization necessarily increases the applied
monitor unit settings. The impact of renormalization on the
mean dose to the GTV was shown in Figure 9. An explana-
tion for this behavior is illustrated in Figure 10. Consider a
scenario in which a relatively large PTV was targeted using
the 95% isodose lines for 95% volume coverage as shown in
Figure 10(a). In this case, the aperture width is such that the
beam penumbra does not impact the majority of the PTV
dose and the dose fall-off outside the PTV is slow. Alterna-
tively, by targeting a relatively small PTV (for the same sized
GTV) as shown in Figure 10(b), the beam penumbras begin
to overlap due to the small field size. In such a case, there is
no homogenous dose region, and the only way to deliver a
desired dose to 95% of the PTV is to prescribe to a lower
isodose line. In doing so, the global maximum dose increases,
as does the absolute dose delivered to the lower isodose lines
and the dose fall-off outside the PTV is fast. Lower than 80%
isodose line prescription plans might be preferred for tumor
control and reduced toxicity.
Plans with 90% isodose line prescription should be limited to
cases where dose homogeneity takes priority, an observation
shared by Ohtakara et al.16 However, the prescription isodose
lines ranged from 70% - 90% in their study making it inad-
equate to determine if 70% was the most optimal. A recent
SRS study on brain lesions had proposed the dose dropping
speed concept by fitting the mean dose in multiple rind
structures around PTV with a double exponential function of
the distance from the PTV surface.17 An observation made in
their study which matched with ours is that a significantly
steep dose falloff and better normal tissue sparing was ob-
served in prescribing to 60% - 70% isodose lines than in 90%
isodose line especially for smaller tumors. While exploring
the wider range of 50% - 90%, the dose dropping speed was
found to increase with decreasing prescription isodose line
and plateaus at 60% - 70% isodose line.
Dose inhomogeneity within the PTV is considered accepta-
ble and even potentially advantageous. In a phantom study
on determining the optimal prescription isodose line for
LINAC-based SBRT, it was found to occur between 59% and
69% for lung tumors which is consistent with our findings.13
This study optimizes for conformity, dosimetric and radiobi-
Volume 3 • Number 2 • 2015 International Journal of Cancer Therapy and Oncology 9
www.ijcto.org
© Narayanasamy et al. ISSN 2330-4049
ological parameters and minimizes normal tissue irradiation.
A Monte Carlo study on SBRT of lung tumor by Widder et
al. concludes that prescribing to an isodose lower than 80%
of the isocenter dose would improve normal tissue sparing.18
None of the above four studies investigated the effect of al-
tered block margins which we have attempted here.
The 90% plan had the worst CI values compared with 60% -
80% plans, but the values were not significantly different. HI
values and mean, maximum PTV dose decreased with in-
creasing prescription isodose line among the 60%-90% plans.
R50% values were shown to be increasing with the prescrip-
tion isodose line with 90% isodose plans having inferior dose
gradient. For all of the plans, values of CI and R50% agree
with the recommended values of RTOG report 0813 within
the specified minor deviation. Although CI values were sim-
ilar across different prescription isodose lines, HI and R50%
values were significantly different in the 60%-70% plans
than in the 80%, 90% plans.
The practice of renormalization in conventional treatment
planning typically involved prescription isodose lines of 95%
- 98% resulting in less than a 5% dose prescription variation
across patients and clinics. In SBRT planning, the normal
tissue sparing can be improved by the choice of prescribed
isodose line in a wider range of 50% - 90%. As the prescrip-
tion isodose line decreases, the dose heterogeneity within
the target increases. In addition, the tolerance of target dose
heterogeneity is clinically relevant even for SBRT. Although
within the target, the global maximum dose in a low isodose
line prescription plan is much higher than in a high isodose
line prescription plan. Caution has to be exercised to ensure
dosimetric conformity during delivery with precise setup
accuracy. The clinical implication of tumor dose heterogene-
ity and tumor control is poorly understood. Further investi-
gation is expected to improve our understanding of impact
that the tumor dose heterogeneity has on tumor control.
Overall, these results indicate that the percentage isodose
line specification affect dose distribution both within the
target and in the normal tissue when the same prescription
dose is administered with same target coverage. Planners
should be aware of the significance and the most optimal
plan has to be selected on a case basis.
Conclusion
The planning, immobilization and set-up techniques used in
our clinic appear to result in set-up reproducibility that re-
sults in agreement between planned and delivered mean
dose to the GTV to within 2%. The planned and delivered
minimum dose to the GTV agreed to within 4%. Tumor
volumes are stable during SBRT, to within the error in vol-
ume measurement. For the small tumors and target volumes
treated with SBRT, we found that traditional margin reduc-
tion techniques do not affect a reduction in the volume of
tissue irradiated to any absolute isodose value. In this study,
plans based on 60%, 70%, 80% and 90% prescription isodose
lines with similar target coverage were compared. Prescrip-
tion to 60% - 70% isodose levels would be beneficial for both
tumor control and normal tissue toxicity. These results call
for further investigation to determine whether the treatment
plans prescribed to lower isodose line can lead to better clin-
ical outcomes.
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